Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Choroid plexus cell replacement therapy - Living Cell Technologies

Drug Profile

Choroid plexus cell replacement therapy - Living Cell Technologies

Alternative Names: Neurological disorders cell therapy - Living Cell Technologies; NeurotrophinCell; NTCELL

Latest Information Update: 20 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Living Cell Technologies
  • Developer Auckland UniServices; Living Cell Technologies; University of Auckland
  • Class Antidementias; Antiparkinsonians; Cell therapies; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Cell replacements; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • Preclinical Hearing loss; Huntington's disease; Wounds
  • Research Alzheimer's disease; Retinal disorders
  • No development reported Osteoarthritis; Osteoporosis; Spinal cord injuries; Stroke

Most Recent Events

  • 02 May 2019 Living Cell Technologies completes a phase II trial in in Parkinson's disease in New Zealand (Intrastriatal) (NCT02683629)
  • 04 Jan 2018 Development is underway for Hearing loss, Retinal disorders and Huntington's disease (9230315; 9230035)
  • 10 Nov 2017 Adverse events and efficacy data from a phase II trial in Parkinson's disease released by Living Cell Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top